Oct 02, 2014 7:35 am EDT Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2
Sep 30, 2014 7:30 am EDT Heat Biologics, Inc. to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday, October 7, 2014
Sep 18, 2014 8:05 am EDT Heat Biologics Commences Patient Dosing in Phase 2 Study of Viagenpumatucel-L for the Treatment of Non-Small Cell Lung Cancer
Sep 04, 2014 7:30 am EDT Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September
Aug 25, 2014 8:05 am EDT Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility
Aug 04, 2014 8:05 am EDT Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies
May 30, 2014 8:05 am EDT Heat Biologics Receives Green Light to Expand Enrollment of Its Phase 1/2 Study of HS-410 in Bladder Cancer Based on Encouraging Preliminary Safety Results
Apr 09, 2014 12:00 pm EDT Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research